The firm funds and co-founds early-stage companies using AI to transform the future of healthcare. The firm invests in US-based techbio and healthtech companies at the Seed and Series A stages, more often at Seed. The typical check sizes range from $0.5M-3M and the firm reserves for follow-on rounds.
The firm’s sectors of focus include biopharma tech and services, precision medicine, life sciences SaaS and tools, novel care delivery, and novel payment models. The firm does not invest in pure therapeutics or medical devices.
The firm does not have strict management team requirements; however, they look for founders who are knowledgeable domain experts with a bold vision for how their company will make a lasting contribution to the advancement of an industry or solve a massive healthcare challenge. As leaders, they build high-functioning teams and earn trust quickly. The firm may take a board or observer seat on a case-by-case basis, but it is not a requirement.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment